In RealClearMarkets, we argued that the EU's Digital Markets Act punishes scale and success and stifles the innovation Europe says it wants.

In Truth on the Market, we argued that NIH's 'access plan' mandate for patent licenses is central planning that threatens biomedical innovation.

In National Review, we argued that a fee on patent value is an unconstitutional, unapportioned property tax that would discourage innovation.